TruScreen Group Limited announced that the private medical services provider, Dr. Sulaiman Al-Habib Medical Group (DSAMG), has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC). A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of DSAMG. The preliminary results confirmed that TruScreen's sensitivity was 83.3% (LBC: 66%) and specificity was 95% (LBC 98%).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 NZD | 0.00% | 0.00% | -21.74% |
13/03 | Truscreen Group Raises Additional NZ$520,000 via Share Placement; Shares Jump 5% | MT |
08/03 | New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.74% | 60.91L | |
+10.03% | 22TCr | |
+13.59% | 19TCr | |
+20.01% | 14TCr | |
+30.83% | 11TCr | |
+2.05% | 6.5TCr | |
+15.38% | 5.3TCr | |
+3.96% | 5.04TCr | |
+8.37% | 4.42TCr | |
+3.27% | 3.64TCr |
- Stock Market
- Equities
- TRU Stock
- News TruScreen Group Limited
- TruScreen Group Limited Announces Clinical Evaluation Results from Saudi Arabia